These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 9764818)

  • 1. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V; Scott RP; Ibáñez CF
    J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
    Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
    Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
    Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
    Hayashi H; Ichihara M; Iwashita T; Murakami H; Shimono Y; Kawai K; Kurokawa K; Murakumo Y; Imai T; Funahashi H; Nakao A; Takahashi M
    Oncogene; 2000 Sep; 19(39):4469-75. PubMed ID: 11002419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
    Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
    Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
    Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Shc docking site on Ret tyrosine kinase.
    Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
    Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
    Scott RP; Eketjäll S; Aineskog H; Ibáñez CF
    J Biol Chem; 2005 Apr; 280(14):13442-9. PubMed ID: 15677445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.
    Durick K; Gill GN; Taylor SS
    Mol Cell Biol; 1998 Apr; 18(4):2298-308. PubMed ID: 9528800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.
    Borrello MG; Pelicci G; Arighi E; De Filippis L; Greco A; Bongarzone I; Rizzetti M; Pelicci PG; Pierotti MA
    Oncogene; 1994 Jun; 9(6):1661-8. PubMed ID: 8183561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells.
    Zhang S; Mantel C; Broxmeyer HE
    J Leukoc Biol; 1999 Mar; 65(3):372-80. PubMed ID: 10080542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.
    Pelicci G; Troglio F; Bodini A; Melillo RM; Pettirossi V; Coda L; De Giuseppe A; Santoro M; Pelicci PG
    Mol Cell Biol; 2002 Oct; 22(20):7351-63. PubMed ID: 12242309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N; Murakami H; Iwashita T; Takahashi M
    J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.